EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

NUT carcinoma (NC) is an aggressive carcinoma driven by the BRD4-NUT fusion oncoprotein, which activates chromatin to promote expression of pro-growth genes. BET bromodomain inhibitors (BETi) impede BRD4-NUT’s ability to activate genes and are thus a promising treatment but limited as monotherapy. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yeying, Durall, R. Taylor, Luong, Nhi M., Hertzler, Hans J., Huang, Julianna, Gokhale, Prafulla C., Leeper, Brittaney A., Persky, Nicole S., Root, David E., Anekal, Praju V., Montero Llopis, Paula D.L.M., David, Clement N., Kutok, Jeffery L., Raimondi, Alejandra, Saluja, Karan, Luo, Jia, Zahnow, Cynthia A., Adane, Biniam, Stegmaier, Kimberly, Hawkins, Catherine E., Ponne, Christopher, Le, Quan, Shapiro, Geoffrey I., Lemieux, Madeleine E., Eagen, Kyle P., French, Christopher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461970/
https://www.ncbi.nlm.nih.gov/pubmed/37645799
http://dx.doi.org/10.1101/2023.08.15.553204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461970/
https://www.ncbi.nlm.nih.gov/pubmed/37645799
http://dx.doi.org/10.1101/2023.08.15.553204

Ejemplares similares